Compare ING Groep NV (ING) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Novartis AG — how do they compare? ING Groep NV trades at $33.36 (market cap $93.76B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 2.9× ING Groep NV's market cap, and ING Groep NV pays the higher dividend (3.95%). Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Novartis AG for 82 Days on average.
| ING | NVS | |
|---|---|---|
Market Cap | $93.76B | $268.57B |
Volume | 4,620,220 | 1,532,573 |
Sector | Financials | Health |
52-Week High | $37.27 | $168.62 |
52-Week Low | $23.66 | $121.80 |
Typical Hold Time | 94 Days | 82 Days |
Enterprise Value | $236.48B | $309.89B |
Dividend Yield | 3.95% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.37, down 1.62% on the day, with a bearish technical signal from moving averages and oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.75 estimate. Revenue for 2025 reached $22.90 billion, with a net income margin of 28.34%, though cash flow trends show persistent net outflows. Analyst consensus is bullish with 11 buy ratings and no sell recommendations.
The outlook for ING is supported by raised ROE targets and organic growth initiatives, but risks include negative cash flows and regulatory scrutiny. The stock offers value with a P/E of 12.86 and dividend yield, yet investors face headwinds from operational cash burn and macroeconomic sensitivity.
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
